Tel Aviv University

Technion Research & Development Foundation Ltd

The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Itai Benhar

Iftach Yacoby

Ehud Gazit

Nathan Nelson

Beka Solomon

Alex Martin Szpilman

Nir Osherov

Vladimir Dergachev

Yariv Mazor

Ronit Rosenfeld

Dan Peer

Doron Shabat

Assaf Shapira

Eliora Z Ron

Sara Orgad

Lilach Vaks

Eliora Ron

Ranit Kedmi

Akiva Vexler

Itay Barnea

Rahamim Ben-Yosef

Meital Gal-Tanamy

Dana Greenfeld

Marina Shamis

Limor Nahary

Nuphar Veiga

Romy Zemel

Ran Tur-Kaspa

A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

Modular platform for targeted therapeutics

An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain. Methods of generating same and uses thereof are also provided.

Bi-and monospecific, asymmetric antibodies and methods of generating the same

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]: wherein R is H, Calkyl or phenyl; Ris (CH)wherein m is between 0 and 4; Rand Rare each independently H or Calkyl, Ris or OH, Ris selected from a group consisting of: amide and alkyl, and Ris a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

Amphotericin B derivatives

Embodiments of the invention provide derivatives of Amphotericin B having increased solubility and reduced toxicity relative to AMB, while retaining antifungal activity against multiple clinical fungal isolates. Derivatives of AMB are provided comprising a polymer group having an amine group, the polymer linked to mycosamine via a relatively stable linker such as an amide linker. The derivatives may be of the general formula [I]: wherein R is H, Calkyl or phenyl; Ris (CH)wherein m is between 0 and 4; Rand Rare each independently H or Calkyl, Ris H or OH, Ris selected from a group consisting of: amide and alkyl, and Ris a water-soluble polymer, and pharmaceutically acceptable salts, solvates, hydrates, diastereomers, and prodrugs of the compound of Formula [I].

An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein:

Bi- and monospecific, asymmetric antibodies and methods of generating the same

The present invention relates to activatable toxin complexes which include a cleavable inhibitory peptide. More specifically, the complexes comprise a cell targeting domain, a toxin catalytic domain, a specific protease cleavage site and an inhibitory peptide domain. The inhibitory peptide prevents the catalytic domain from exerting toxic effects until its release from the complex by the action of a protease, such a viral protease, at the protease cleavage site. Further provided are pharmaceutical compositions comprising the complexes and use thereof for treating infections and malignant disease.

Activatable toxin complexes comprising a cleavable inhibitory peptide

An isolated polypeptide comprising a hydrogen generating enzyme attached to a heterologous ferredoxin is disclosed, as well as polynucleotides encoding same, nucleic acid constructs capable of expressing same and cells expressing same. A method for generating hydrogen using the isolated polypeptide is also disclosed.

Photocatalytic hydrogen production and polypeptides capable of same

A cyanobacterial cell comprising a PSI complex which accepts electrons from at least one respiratory cytochrome is disclosed. Methods of generating same and use of same for the production of hydrogen gas are also disclosed.

Photocatalytic hydrogen production in cyanobacteria

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form ofexotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Recombinant fusion protein and polynucleotide construct for immunotoxin production

Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.

Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses

The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions.

Growing community of inventors

Rehovot, Israel

Itai Benhar